PD1-blockade combinations in pancreatic ductal adenocarcinoma have been poorly effective, and the underlying reasons for this are unknown. A recent study revealed that chemoradiation plus PD1-blockade reinvigorates tumor-specific T cells; however, this T-cell activation is accompanied with exaggerated NFkB signaling, which may limit productive tumor-controlling immunity.

Original languageEnglish
Pages (from-to)474-476
Number of pages3
JournalClinical Cancer Research
Issue number3
StatePublished - Feb 1 2024


Dive into the research topics of 'Pancreatic Cancer’s PD1-Roadblock: When T-Cell Reinvigoration Is Not Enough'. Together they form a unique fingerprint.

Cite this